<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>osteoporosis geriatrics &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/osteoporosis-geriatrics/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 00:38:14 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>osteoporosis geriatrics &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>ロモソズマブとテリパラチドの持続性比較</title>
		<link>https://bioengineer.org/%e3%83%ad%e3%83%a2%e3%82%bd%e3%82%ba%e3%83%9e%e3%83%96%e3%81%a8%e3%83%86%e3%83%aa%e3%83%91%e3%83%a9%e3%83%81%e3%83%89%e3%81%ae%e6%8c%81%e7%b6%9a%e6%80%a7%e6%af%94%e8%bc%83/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 00:37:46 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Aging population osteoporosis** **Açıklama:** 1. **Romosozumab vs teriparatide persistence:** Çalışmanın temel konusu olan iki ilacın tedavi devamlılığının doğrudan karşıla]]></category>
		<category><![CDATA[Elderly Japanese cohort]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **Romosozumab vs teriparatide persistence]]></category>
		<category><![CDATA[Japanese elderly]]></category>
		<category><![CDATA[Long-term bone therapy]]></category>
		<category><![CDATA[Makalenin içeriğine uygun 5 etiket: **romosozumab persistence]]></category>
		<category><![CDATA[osteoporosis geriatrics]]></category>
		<category><![CDATA[Osteoporosis treatment adherence]]></category>
		<category><![CDATA[romosozumab kullananlarda tedavi sürekliliğinin daha yüksek olmasıdır. Doğrudan]]></category>
		<category><![CDATA[teriparatide adherence]]></category>
		<category><![CDATA[treatment continuation** **Açıklama:** 1. **romosozumab persistence:** Çalışmanın temel bulgusu]]></category>
		<guid isPermaLink="false">https://bioengineer.org/%e3%83%ad%e3%83%a2%e3%82%bd%e3%82%ba%e3%83%9e%e3%83%96%e3%81%a8%e3%83%86%e3%83%aa%e3%83%91%e3%83%a9%e3%83%81%e3%83%89%e3%81%ae%e6%8c%81%e7%b6%9a%e6%80%a7%e6%af%94%e8%bc%83/</guid>

					<description><![CDATA[In a significant advancement in osteoporosis treatment, recent population-based cohort studies have highlighted the comparative persistence of romosozumab and teriparatide in older Japanese adults aged 75 years and above. Osteoporosis, a prevalent condition among the elderly, especially affects bone health, increasing fracture risk and leading to severe health consequences. This study sheds light on long-term [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320081</post-id>	</item>
	</channel>
</rss>
